Pfizer has announced this Tuesday that they have begun testing oral COVID 19 treatment as well as intravenous antivirals.
Both treatments would be the first of its kind in the fight against COVID 19.
According to a press release by the pharmaceutical company, phase 1 will be tested on healthy adults “to evaluate the safety and tolerability of an investigational, novel oral antiviral therapeutic”.
The treatments rely on protease inhibitors, which is the same technology used in the treatment of HIV and hepatitis C.
“Tackling the COVID-19 pandemic requires both preventions via vaccine and targeted treatment for those who contract the virus,” said Mikael Dolsten, MD, PhD., Chief Scientific Officer and President, Worldwide Research, Development and Medical of Pfizer, in a statement.